Assessment of Spontaneous Baroreflex Sensitivity in Carriers of Implantable Cardioverter Defibrillators: Association With Disorders of the Ventricular Heart Rate. Case-control Study

Not Applicable

Completed

• Conditions: Myocardial Infarction
• Interventions: Other: Baroreflex assessment

• Registration Number: NCT02930382
• Lead Sponsor: Poitiers University Hospital

Brief Summary

We must implement 8 implantable cardioverter defibrillators (ICDs) to save a life in 3 years after myocardial infarction (MI) in primary prevention.

Left ventricular ejection fraction (LVEF) is proposed as the one tool predicting sudden cardiac death after MI.

Several studies have shown that impairment of spontaneous baroreflex sensitivity (BRS) after MI was predictor of sudden death.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-05-26
• Primary Completion: 2016-05-26
• Study Completion: 2016-05-26
• Study First Submitted: 2016-10-10
• Study First Submitted QC: 2016-10-11
• Study First Posted: 2016-10-12
• Status Verified: 2018-08
• Last Update Submitted: 2018-08-06
• Last Update Posted: 2018-08-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

• Patients implanted with an implantable cardioverter defibrillator for primary prevention of of cardiac sudden death, ischaemic cardiomyopathy
• Implantable cardioverter defibrillators implantation for at least 3 years
• Age ≥ 18 years

Exclusion Criteria

• ventricular or atrial pacing ≥1%,
• atrial fibrillation history
• age under 18 years

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
BAROREFLEX	Baroreflex assessment	-

Primary Outcome Measures

Name	Time	Method
spontaneous baroreflex sensitivity by the sequence method (mean slope)	10 days

Trial Locations

Locations (1)

CHU DE Poitiers; 🇫🇷 Poitiers, France